ArriVent BioPharma (NASDAQ:AVBP) presented Phase I data for ARR-217, its CDH17-targeting antibody-drug conjugate, or ADC, in ...
ArriVent BioPharma, Inc. announced initial Phase 1 results for ARR-217 (MRG007), a cadherin-17-targeting antibody-drug conjugate developed in partnership with Lepu Biopharma Co., Ltd. The data, ...
The TCW Concentrated Large Cap Growth Fund Q3 2026 Commentary details tech sector performance and strategic stock holdings.
Additionally, the company launched two new AI-driven products in October 2026 to address emerging regulatory requirements and ...
Core operating income expected to be in line to grow low single-digit (from decline low single-digit) ...
ArriVent BioPharma (NASDAQ:AVBP) delivered early oncology updates with initial Phase 1 results for ARR-217, an investigational antibody-drug conjugate targeting cadherin-17 (CDH17). The candidate, ...
AI selloff nears a bottom as SMH rotates into financials and software. Click for a look at the tech sector and its key ...
Total revenue increased 7% to a record $11.0M from $10.2M in the same prior year period. During 2026, the Company has reduced ...
AudioEye Q3 2026 revenue reached a record $11 million as adjusted EBITDA rose 58%. Management raised full-year EBITDA ...
Vaisala Corporation Interim Report January–September 2026 October 27, 2026, at 9:00 a.m. (EET) Vaisala Corporation Interim Report ...
AR Rahman’s net worth, film composition fees, music royalties and business ventures offer a glimpse into the fortune built by ...
Novartis' oral BTK inhibitor remibrutinib (Rhapsido) met its primary endpoint in Phase III REMODEL-1 and REMODEL-2 relapsing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results